Mercyhealth, a seven-hospital system in Illinois and Wisconsin serving 2.4 million patients annually, implemented autonomous AI coding to handle growing claim volumes from increased physician and ER visits. Director of coding and CDI Kelly Pierson says the tool improved revenue cycle performance. Source: Healthcare Finance News.

Impact · Mid-size health systems now have a peer-validated case for AI-driven coding. Revenue cycle teams under volume pressure can point to Mercyhealth's experience when building internal business cases. This accelerates the timeline for autonomous coding becoming table stakes rather than competitive advantage.

Action · Revenue cycle leaders at systems with rising visit volumes should request a structured demo or pilot proposal from at least two autonomous AI coding vendors this quarter, benchmarking against Mercyhealth's reported gains.

STAT News reports that one year after DOGE-initiated cuts, six former FDA staffers describe loss of institutional expertise and work they 'never thought they'd leave.' The article details how regulatory review capacity and safety surveillance have been degraded. Source: STAT News.

Impact · Longer FDA review timelines and thinner safety surveillance create downstream effects for health systems planning formulary additions, device procurement cycles, and clinical trial participation. Pharma and device companies face increased regulatory uncertainty.

Action · Health system pharmacy and clinical leadership should extend their new-product pipeline planning horizons by 3-6 months to account for slower FDA throughput, and build contingency sourcing for any products awaiting approval.

Italian firm Angelini Pharma is acquiring Catalyst Pharmaceuticals, maker of rare disease neurology drugs including Firdapse, for $4.1 billion. Source: STAT News.

Impact · Cross-border rare-disease M&A at this scale reinforces that specialty neurology assets command premium valuations. Health systems with rare-disease centers of excellence should anticipate potential pricing or supply-chain transitions as ownership changes. Competing rare-disease companies may face increased acquisition interest.

Action · Health system pharmacy directors should contact Catalyst/Angelini transition teams to confirm supply continuity for Firdapse and any pipeline products; rare-disease clinicians should monitor for formulary or access-program changes post-close.

KFF Health News reports that while some drug prices have dropped under the TrumpRx program, many others have risen. Separately, the TrumpRx reliance on manufacturer discount coupons creates hidden cost exposure for insured patients, as coupon use can increase total out-of-pocket spending by bypassing insurance benefit accumulation. Source: KFF Health News.

Impact · Health systems and physician practices face a more complex patient-financial-counseling environment. Patients presenting manufacturer coupons may not realize they are undermining their own insurance cost-sharing accumulation. Revenue cycle and patient access teams need updated workflows to counsel patients appropriately.

Action · Patient financial services directors should update counseling scripts and training materials to address manufacturer coupon risks under TrumpRx, ensuring front-line staff can explain how coupons interact with deductibles and out-of-pocket maximums.